Free Trial

ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Position Lowered by Perceptive Advisors LLC

ADMA Biologics logo with Medical background

Perceptive Advisors LLC cut its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 7.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,433,369 shares of the biotechnology company's stock after selling 550,950 shares during the quarter. Perceptive Advisors LLC owned 2.85% of ADMA Biologics worth $29,079,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of ADMA Biologics by 2.7% during the 3rd quarter. Vanguard Group Inc. now owns 12,781,695 shares of the biotechnology company's stock valued at $45,758,000 after purchasing an additional 336,190 shares in the last quarter. Stonepine Capital Management LLC grew its stake in ADMA Biologics by 1.3% in the 4th quarter. Stonepine Capital Management LLC now owns 9,222,617 shares of the biotechnology company's stock valued at $41,686,000 after acquiring an additional 118,342 shares during the period. Invesco Ltd. grew its stake in ADMA Biologics by 8.5% in the 3rd quarter. Invesco Ltd. now owns 5,417,166 shares of the biotechnology company's stock valued at $19,393,000 after acquiring an additional 426,446 shares during the period. American Century Companies Inc. grew its stake in ADMA Biologics by 20.8% in the 3rd quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company's stock valued at $17,514,000 after acquiring an additional 840,761 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its stake in ADMA Biologics by 15.1% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 3,767,558 shares of the biotechnology company's stock valued at $13,488,000 after acquiring an additional 493,000 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.


Insiders Place Their Bets

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of the business's stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the sale, the chief executive officer now directly owns 2,081,475 shares in the company, valued at $22,313,412. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of the business's stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the sale, the chief executive officer now directly owns 2,081,475 shares in the company, valued at $22,313,412. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve Elms sold 49,887 shares of the business's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $6.01, for a total transaction of $299,820.87. Following the sale, the director now owns 2,527,500 shares in the company, valued at $15,190,275. The disclosure for this sale can be found here. Insiders own 3.70% of the company's stock.

Analyst Upgrades and Downgrades

ADMA has been the topic of several recent research reports. Mizuho lifted their target price on shares of ADMA Biologics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Friday, May 10th. Raymond James boosted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a "strong-buy" rating in a research report on Friday, May 10th. Cantor Fitzgerald boosted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company an "overweight" rating in a research report on Friday, May 10th. Finally, HC Wainwright boosted their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a "buy" rating in a research report on Friday, May 10th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $10.50.

Read Our Latest Report on ADMA Biologics

ADMA Biologics Trading Down 1.4 %

ADMA traded down $0.15 on Friday, hitting $10.63. The company had a trading volume of 2,385,816 shares, compared to its average volume of 2,814,956. The firm has a market cap of $2.46 billion, a P/E ratio of -531.50 and a beta of 0.48. ADMA Biologics, Inc. has a 1 year low of $3.06 and a 1 year high of $10.85. The company's fifty day moving average price is $8.17 and its 200 day moving average price is $6.23. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.03. The firm had revenue of $81.90 million for the quarter, compared to analyst estimates of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. ADMA Biologics's revenue was up 43.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.03) EPS. As a group, equities analysts expect that ADMA Biologics, Inc. will post 0.35 earnings per share for the current year.

ADMA Biologics Profile

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Articles

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Should you invest $1,000 in ADMA Biologics right now?

Before you consider ADMA Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.

While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines